EXPLORE!

Role of rosuvastatin therapy in children with heterozygous familial hypercholesterolemia

  1325 Views

eMediNexus    27 December 2017

A study published in the Circulation journal evaluated the impact of 2-year treatment with rosuvastatin on carotid intima media thickness in children with heterozygous familial hypercholesterolemia (HeFH). The study cohort involved children with HeFH (age: 6 – < 18 years) and low-density lipoprotein cholesterol > 4.9 mmol/L or > 4.1 mmol/L in combination with other risk factors. They were administered rosuvastatin for 2 years, starting at 5 mg once daily, with up-titration to 10 mg (age: 6 – < 10 years) or 20 mg (age: 10 – < 18 years). The findings revealed that rosuvastatin therapy led to significantly less progression of increased carotid intima media thickness in children with HeFH than in untreated unaffected siblings. The researchers also emphasized the importance of early commencement of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.